FCE 22891对慢性阻塞性肺疾病急性加重期患者的临床、细菌学疗效及耐受性
Clinical and bacteriological efficacy and tolerability of FCE 22891 in patients with exacerbations of chronic obstructive pulmonary disease.
作者信息
Boersma W G, Puister S M, van Altena R, de Vries-Hospers H G, Molinari M, Koëter G H
机构信息
Department of Pulmonary Diseases, University Hospital Groningen, The Netherlands.
出版信息
Antimicrob Agents Chemother. 1994 Apr;38(4):872-5. doi: 10.1128/AAC.38.4.872.
A beta-lactamase-stable antibiotic, the oral penem FCE 22891 (ritipenem acoxil), was investigated for use in exacerbations of chronic obstructive pulmonary disease (COPD). Thirteen of the 15 COPD patients had a proven lower respiratory tract infection. Symptom scores and forced expiratory volumes in 1 s significantly improved during therapy with FCE 22891 in combination with bronchodilators and intravenous corticosteroids. Conversion of representative sputum to nonrepresentative sputum or eradication of the original pathogen in representative sputum was effected in 12 patients. Resistance to FCE 22891 was observed in three cases with Haemophilus influenzae. Gastrointestinal disturbances, of which one was severe, were experienced by eight patients. Although FCE 22891 has some beneficial effect in exacerbations of COPD, there are reservations about its use because of adverse effects and potential inefficacy in the treatment of infection with H. influenzae.
一种对β-内酰胺酶稳定的抗生素——口服青霉烯类药物FCE 22891（利替培南酯），被用于慢性阻塞性肺疾病（COPD）急性加重期的研究。15例COPD患者中有13例被证实存在下呼吸道感染。在FCE 22891联合支气管扩张剂及静脉用糖皮质激素治疗期间，症状评分及第1秒用力呼气容积显著改善。12例患者的代表性痰液转为非代表性痰液或原病原体在代表性痰液中被清除。3例流感嗜血杆菌感染病例出现了对FCE 22891的耐药。8例患者出现胃肠道不适，其中1例严重。尽管FCE 22891在COPD急性加重期有一定有益作用，但由于其不良反应以及在治疗流感嗜血杆菌感染时可能无效，对其使用仍存在疑虑。
Zotero 插件